A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 125 participants.
Also called NCT03152552
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 125 participants
- Sponsor
- Registry
-
NCT03152552 -
2016-003084-19
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, Germany, Hungary, Ireland, Italy, Mexico, Netherlands, Norway, Poland, Puerto Rico, Singapore, South Africa, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT03152552. Randomized; triple masking; primary purpose treatment. Start 2017-07-25 (actual); primary completion 2018-06-06 (actual). Results posted on 2019-08-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
- Condition
- Diabetes Mellitus and Heart Failure
- Intervention (Drug)
- LIK066
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Empagliflozin
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct03152552- Content hash
8c6c99a674a0a5c49bea50ea9f70dc8a52be14a0a86ef5fad210433a5d3f7921